On May 15, 2025, Benitec Biopharma (BNTC, Financial) received an update from JMP Securities regarding its analyst rating and price target. The stock continues to be rated as "Market Outperform" by analyst Silvan Tuerkcan.
The current price target for Benitec Biopharma (BNTC, Financial) remains unchanged at $20.00 USD. This reiteration indicates that JMP Securities maintains confidence in the potential performance of Benitec Biopharma (BNTC) in the market. The price target prior to this update was also set at $20.00 USD, showing no change in expectations.
Benitec Biopharma (BNTC, Financial) is listed on the NASDAQ exchange and continues to garner attention from investors due to its market positioning and performance expectations. JMP Securities' decision to maintain both the rating and price target reflects a steady outlook for the company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Benitec Biopharma Inc (BNTC, Financial) is $25.71 with a high estimate of $35.00 and a low estimate of $17.00. The average target implies an upside of 81.58% from the current price of $14.16. More detailed estimate data can be found on the Benitec Biopharma Inc (BNTC) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Benitec Biopharma Inc's (BNTC, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Benitec Biopharma Inc (BNTC, Financial) in one year is $0.22, suggesting a downside of 98.45% from the current price of $14.1612. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Benitec Biopharma Inc (BNTC) Summary page.
